Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17477018 | 0.92 | RAB9A (0.39) | PDE10AKDM4EALDH1A1TP53HPGD | |
| SCHEMBL17477017 | 0.92 | PDE4B (0.39) | PDE10AKEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL17476964 | 0.91 | KEAP1 (0.37) | PDE10AKEAP1NFE2L2CFTR | |
| SCHEMBL17476985 | 0.88 | GRIN2B (0.35) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL17477051 | 0.87 | RAB9A (0.39) | KDM4EALDH1A1TP53HPGDRAB9A | |
| SCHEMBL17476994 | 0.87 | RAB9A (0.37) | KDM4EALDH1A1TP53HPGDRAB9A | |
| SCHEMBL17476961 | 0.86 | CFTR (0.33) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL17477026 | 0.86 | PDE4B (0.44) | RAB9A | |
| SCHEMBL17476894 | 0.86 | S1PR1 (0.36) | TP53RAB9A | |
| SCHEMBL17476901 | 0.86 | KEAP1 (0.35) | PDE10AKEAP1NFE2L2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986600-B1 | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9527832-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2016-12-27 | — | — | US | disclosed |
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | TYMP, PDE4A, DPYD | PDE10A 48/4885KEAP1 1772/4885NFE2L2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.